Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

NCT ID: NCT01106014

Last Updated: 2025-10-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1156 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-12-01

Study Completion Date

2014-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Selexipag is up-titrated from Day 1 to Week 12 to each patient's maximum tolerated dose in the range of 200-1600 µg twice a day (b.i.d.) in 200 µg steps starting with one 200 µg oral tablet on Day 1. From Day 2 onwards, a b.i.d. dose regimen with an interval of approximately 12 hours is followed. If this dose (selexipag 200 μg b.i.d.) is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg. Up-titration is followed by a stable maintenance treatment period from Week 12 onwards, up to Week 26, at the maximum tolerated dose

Group Type EXPERIMENTAL

Selexipag

Intervention Type DRUG

Selexipag 200 µg tablets

2

Matching placebo is administered orally with a dosing interval of approximately12 h. A (mock) up-titration scheme is followed

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo tablets matching selexipag

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Selexipag

Selexipag 200 µg tablets

Intervention Type DRUG

Placebo

Placebo tablets matching selexipag

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ACT-293987

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients 18-75 years old, with symptomatic PAH
* PAH belonging to the following subgroups of the updated Dana Point Clinical Classification Group 1 (Idiopathic, or Heritable, or Drug or toxin induced, or Associated (APAH) with Connective tissue disease, Congenital heart disease with simple systemic-to-pulmonary shunt at least 1 year after surgical repair, or HIV infection)
* Documented hemodynamic diagnosis of PAH by right heart catheterization, performed at any time prior to Screening
* Six minute walk distance (6MWD) between 50 and 450 m at Screening within 2 weeks prior to the Baseline Visit
* Signed informed consent

* Patients who have received prostacyclin or its analogs within 1 month before Baseline Visit, or are scheduled to receive any of these compounds during the trial
* Patients with moderate or severe obstructive lung disease
* Patients with moderate or severe restrictive lung disease
* Patients with moderate or severe hepatic impairment (Child-Pugh B and C)
* Patients with documented left ventricular dysfunction
* Patients with severe renal insufficiency
* Patients with BMI \<18.5 Kg/m2
* Patients who are receiving or have been receiving any investigational drugs within 1 month before the Baseline Visit
* Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements, in particular with 6MWT
* Recently conducted or planned cardio-pulmonary rehabilitation program based on exercise training
* Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements
* Life expectancy less than 12 months
* Females who are lactating or pregnant or plan to become pregnant during the study
* Known hypersensitivity to any of the excipients of the drug formulations
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Actelion

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Aline Frey

Role: STUDY_DIRECTOR

Actelion

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of South Alabama

Mobile, Alabama, United States

Site Status

The University of Arizona, Clinical and Translational Science (CATS) Research Center

Tucson, Arizona, United States

Site Status

University of California San Diego Medical Center (La Jolla)

La Jolla, California, United States

Site Status

Cedars-Sinai Medical Center

Los Angeles, California, United States

Site Status

GLVA Healthcare Center

Los Angeles, California, United States

Site Status

University of California, Davis, UC Davis Medical Center

Sacramento, California, United States

Site Status

LIU Center for Pulmonary Hypertension

Torrance, California, United States

Site Status

Lung Health & Sleep Emhancement Center, LLC

Newark, Delaware, United States

Site Status

Emory University School of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

Atlanta, Georgia, United States

Site Status

Georgia Health Sciences University

Augusta, Georgia, United States

Site Status

Georgia Clinical Research

Austell, Georgia, United States

Site Status

Clarian North Hospital

Carmel, Indiana, United States

Site Status

University of Iowa Hospitals & Clinics

Iowa City, Iowa, United States

Site Status

Kentuckiana Pulmonary Associates

Louisville, Kentucky, United States

Site Status

LSU Health Science Center - New Orleans

New Orleans, Louisiana, United States

Site Status

Johns Hopkins University School of Medicine

Baltimore, Maryland, United States

Site Status

Tufts Medical Center

Boston, Massachusetts, United States

Site Status

Massachusetts General Hospital - Pulmonary Critical Care Unit

Boston, Massachusetts, United States

Site Status

Massachusetts General Hospital-Pulmonary Critical Care Unit

Boston, Massachusetts, United States

Site Status

Boston University School of Medicine / Boston University Medical Center

Boston, Massachusetts, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

Beaumont Hospital

Troy, Michigan, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Newark Beth Isreal Medical Center-Department of Pulmonary Medicine

Newark, New Jersey, United States

Site Status

Columbia University Medical Center, Pediatric Cardiology

New York, New York, United States

Site Status

Montefiore Medical Center, Weiler Division

The Bronx, New York, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

The Lindner Clinical Trial Center

Cincinnati, Ohio, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

University Hospitals Case Medical Center

Cleveland, Ohio, United States

Site Status

The Ohio State University Medical Center

Columbus, Ohio, United States

Site Status

Oregon Pulmonary Associates, PC

Portland, Oregon, United States

Site Status

Central Bucks Specialists

Doylestown, Pennsylvania, United States

Site Status

Penn Presbyterian Medical Center

Philadelphia, Pennsylvania, United States

Site Status

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Vanderbilt Medical Center

Nashville, Tennessee, United States

Site Status

UT Southwestern Medical Center at Dallas

Dallas, Texas, United States

Site Status

Baylor College of Medicine

Houston, Texas, United States

Site Status

University of Texas-Houston Health Center Department of Pulmonary & Critical Care

Houston, Texas, United States

Site Status

University of Wisconsin Hospital-Department of Medicine

Madison, Wisconsin, United States

Site Status

St. Luke's Medical Center

Milwaukee, Wisconsin, United States

Site Status

Froedtert Hospital - Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

Centro de Investigacion y Prevencion Cardiovascular (CIPREC)

Buenos Aires, , Argentina

Site Status

Sanatorio Otamendi y Miroli S.A.

Buenos Aires, , Argentina

Site Status

Hospital Britanico-Pneumology

Buenos Aires, , Argentina

Site Status

Sanatorio San Jose

Buenos Aires, , Argentina

Site Status

Instituto De Cardiologia de Corrientes

Corrientes, , Argentina

Site Status

Hospital Privado Centro Medico de Cordoba S.A.

Córdoba, , Argentina

Site Status

St. Vincent's Hospital / Heart and Lung Transplant Unit

Darlinghurst, New South Wales, Australia

Site Status

Prince Charles Hospital Lung Transplant, Thoracic Department

Chermside, Queensland, Australia

Site Status

Royal Adelaide Hospital, Cardiovascular Investigation Unit (CVIU)

Adelaide, South Australia, Australia

Site Status

Flinders Medical Centre, Pulmonary Hypertension, c/- Cardiology

Bedford Park, South Australia, Australia

Site Status

St Vincent's Hospital

Fitzroy, Victoria, Australia

Site Status

Royal Hobart Hospital, Centre for Clinical Research

Hobart, , Australia

Site Status

John Hunter Hospital Autoimmune Resource and Research Centre

New Lambton, , Australia

Site Status

Royal Melbourne Hospital, Department of Respiratory and Sleep Medicine

Parkville, , Australia

Site Status

Royal Perth Hospital

Perth, , Australia

Site Status

Medizinische Universität Graz

Graz, , Austria

Site Status

Medical University of Vienna and AKH Cardiology

Vienna, , Austria

Site Status

The Republican Scientific-Practical Center "Cardiology"

Minsk, , Belarus

Site Status

Minsk City Hospital No. 9

Minsk, , Belarus

Site Status

Minsk Regional Clinical Hospital of the Red Banner of Labour

Minsk, , Belarus

Site Status

Ulb Erasme, Cardiology

Brussels, , Belgium

Site Status

University Hospital Gasthuisberg - Pneumologie

Leuven, , Belgium

Site Status

University of Alberta Hospital - Children's Centre

Edmonton, Alberta, Canada

Site Status

Vancouver General Hospital

Vancouver, British Columbia, Canada

Site Status

Health Sciences Centre

Winnipeg, Manitoba, Canada

Site Status

University of Ottawa Heart Institute

Ottawa, Ontario, Canada

Site Status

University Health Network

Toronto, Ontario, Canada

Site Status

Hopital General Juif (Jewish General Hospital)

Montreal, Quebec, Canada

Site Status

Institut Universitaire de Cardiologie et de Pneumologie de Quebec

Québec, Quebec, Canada

Site Status

Instituto Nacional del Torax Teaching Dept

Santiago, , Chile

Site Status

Clinica Tabancura- Cardiology Unit

Santiago, , Chile

Site Status

Pontificia Universidad Catolica de Chile-Departmento De Enfermedades Cardiovasculares

Santiago, , Chile

Site Status

Peking Union Medical College Hospital, Rheumatology Department

Beijing, , China

Site Status

Cardiovascular Institute & Fuwai Hospital-Pulmonary Vascular Center

Beijing, , China

Site Status

Beijing Shijitan Hospital

Beijing, , China

Site Status

Guangdong General Hospital, Cardiology Department

Guangzhou, , China

Site Status

Renji Hospital, Rheumatology Department

Shanghai, , China

Site Status

Renji Hospital, Cardiology Department

Shanghai, , China

Site Status

Shanghai Pulmonary Hospital, Department of Pulmonary Circulation

Shanghai, , China

Site Status

Fundacion Cardio Infantil

Bogotá, , Colombia

Site Status

Fundacion Clinica Shaio

Bogotá, , Colombia

Site Status

Gen Faculty Hosp Prague Cardiology Clin

Prague, , Czechia

Site Status

Aarhus University Hospital , Cardiology

Aarhus, , Denmark

Site Status

Rigshospitalet, Hjertemedicinsk klinik - Cardiology

Copenhagen, , Denmark

Site Status

Hosp Pradel Lyon - Dpt Pneumology

Bron, , France

Site Status

Hosp Cote de Nacre - Dpt Pneumology

Caen, , France

Site Status

Hosp A. Beclere - Dept Pulmo & Resp Intensive Care

Clamart, , France

Site Status

Hosp Huriez - Dpt Internal Medecine

Lille, , France

Site Status

Hosp Civil - Dpt Pneumology

Strasbourg, , France

Site Status

Hosp Larrey - Dpt Pneumology

Toulouse, , France

Site Status

DRK Kliniken Köpenick

Berlin, , Germany

Site Status

"Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin (Kardiologie, Pneumologie, Angiologie und Intensivmedizin)"

Cologne, , Germany

Site Status

Universitätsklinikum Carl Gustav Carus, Medizinische Klinik1-Pneumologie/MK1-A13

Dresden, , Germany

Site Status

"Justus-Liebig-Universität Gießen Zentrum für Innere Medizin Medizinische Klinik II"

Giessen, , Germany

Site Status

Universität Greifswald / Klinik für Innere Medizin B

Greifswald, , Germany

Site Status

Medizinische Hochschule Hannover / Klinik für Pneumologie

Hanover, , Germany

Site Status

Thoraxklinik am Universitätsklinikum Heidelberg

Heidelberg, , Germany

Site Status

Praxis für Pneumologie und Allergologie

Leipzig, , Germany

Site Status

Klinik Löwenstein gGmbH, Medizinische Klinik 1, Pneumologie - Kardiologie

Löwenstein, , Germany

Site Status

Universitätsklinkum Regensburg / Innere Medizin II

Regensburg, , Germany

Site Status

Onasseio Cardiosurgical Hospital

Athens, , Greece

Site Status

"Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály"

Budapest, , Hungary

Site Status

"Semmelweis Egyetem, Pulmonológiai Klinika"

Budapest, , Hungary

Site Status

Egészségügyi Járóbeteg Központ Kardiológiai Intézete - Debrecen

Debrecen, , Hungary

Site Status

"Pécsi Tudományegyetem Klinikai Központ,

Pécs, , Hungary

Site Status

"Szegedi Tudományegyetem ÁOK Szent-Györgyi Albert Klinikai Központ, II. sz. Belgyógyászati klinika és Kardiológiai központ"

Szeged, , Hungary

Site Status

Sanjivani Hospitals - Department of Cardiology

Ahmedabad, , India

Site Status

Apollo Hospitals, Chennai

Chennai, , India

Site Status

Frontier Lifeline Hospitals, Dr KM Cherian Heart Foundation, Chennai

Chennai, , India

Site Status

CARE Hospitals Nampally, Cardiology Dep. Hyderabad

Hyderabad, , India

Site Status

Apollo Indraprastha Hospitals

New Delhi, , India

Site Status

Mater Miscordiae University Hospital

Dublin, , Ireland

Site Status

Carmel Medical Center, Pulmonary Unit

Haifa, , Israel

Site Status

Pulmonology Institute, Hadassah University Hospital at Ein Karem

Jerusalem, , Israel

Site Status

Rabin Medical Centre - Pulmonology

Petach Tikvah, , Israel

Site Status

Kaplan Medical - Pulmonary Institute

Rehovot, , Israel

Site Status

The Chaim Sheba Med Ctr -Pulmonology

Tel Litwinsky, , Israel

Site Status

Policlinico S. Orsola-Malpighi - Dipartimento Cardio-Toraco-Vascolare

Bologna, , Italy

Site Status

Seconda Università Degli Studi di Napoli - Azienda Universitaria Policlinico - Dipartimento Assistenziale di medicina Generale, Angiologia, Endocrinologia, Epatogastroenterologia e Reumatologia - Unità Operativa di Reumatologia

Napoli, , Italy

Site Status

ISMETT - Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione - Dipartimento di Medicina - Divisione di Pneumologia

Palermo, , Italy

Site Status

Institut Jantung Negara (National Heart Institute)

Kuala Lumpur, , Malaysia

Site Status

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubrian

Mexico City, , Mexico

Site Status

Instituto Nacional de Cardiologia (INC) Ignacio Chavez

Mexico City, , Mexico

Site Status

VU Medisch Centrum / Afdeling longziekten, secretariaat 4A 48

Amsterdam, , Netherlands

Site Status

Academisch Ziekenhuis Maastricht / Department of Pulmonary Diseases

Maastricht, , Netherlands

Site Status

St. Antonius Ziekenhuis afdeling Longziekten

Nieuwegein, , Netherlands

Site Status

Erasmus Medisch Centrum Rotterdam afdeling longziekten

Rotterdam, , Netherlands

Site Status

Hospital Nacional Edgardo Rebagliati / Unidad de Investigacion Cardiologia 2

Lima, , Peru

Site Status

Instituto de Enfermedades Respiratorias Clinica San Gabriel

Lima, , Peru

Site Status

"Uniwersyteckie Centrum Kliniczne II Klinika Kardiologii i Elektroterapii Serca"

Gdansk, , Poland

Site Status

"Instytut Kardiologii Collegium Medium UJ Krakowski Szpital Specjalistyczny im Jana Pawła II Klinika Chorób Serca i Naczyń"

Krakow, , Poland

Site Status

"Wojewódzki Specjalistyczny Szpital im. dr Władysława Biegańskiego Oddział Kardiologiczny, II Katedra i Klinika Kardiologii UM"

Lodz, , Poland

Site Status

"Instytut Gruźlicy i Chorób Płuc Klinika Chorób Wewnętrznych Klatki Piersiowej"

Warsaw, , Poland

Site Status

"Institutul de Pneumologie "Marius Nasta", I. Clinica de Pneumoftiziologie"

Bucharest, , Romania

Site Status

"Spitalul Clinic de Pneumoftiziologie Iasi Sectia Clinica I de Pneumoftiziologie"

Iași, , Romania

Site Status

Municipal Medical Institution City Hospital #5

Barnaul, , Russia

Site Status

Kemerovo Cardiology Dispensary / Kemerovo Regional Hospital

Kemerovo, , Russia

Site Status

Scientific Research Institute of Pulmonology of the Federal Medical and Biological Agency of Russia

Moscow, , Russia

Site Status

State Institution, "Institute fo Rheumatology of RAMS"

Moscow, , Russia

Site Status

The Institution of the Clinical Cardiology named after A. L. Myaskinov

Moscow, , Russia

Site Status

Limited liability company, Consultative diagnostic centre Healthy Joints

Novosibirsk, , Russia

Site Status

V. A. Almazov Institute of Cardiology, Russian Ministry of Healthcare and Social Development / Medical Treatment and Rehabilitation Complex

Saint Petersburg, , Russia

Site Status

Cardiology Scientific Research Institute of Tomsk Scientific Center of RAMs, Siberian Branch / Cardiovascular Surgery Department

Tomsk, , Russia

Site Status

Tomsk Regional Clinical Hospital/ Pulmonology Unit

Tomsk, , Russia

Site Status

Regional Clinical Hospital # 1

Yekaterinburg, , Russia

Site Status

"Klinički Centar Srbije, Klinika za pulmologiju"

Belgrade, , Serbia

Site Status

"Kliničko-bolnički centar Zemun, Kardiološko odeljenje"

Belgrade, , Serbia

Site Status

National Heart Centre (NHC) Singapore

Singapore, , Singapore

Site Status

Národný ústav srdcových a cievnych chorôb, a.s. - NÚSCH a.s.

Bratislava, , Slovakia

Site Status

Gil Medical Centre

Incheon, , South Korea

Site Status

Seoul Nathional University Hospital

Seoul, , South Korea

Site Status

Yonsei University Health System Dept of Cardiology

Seoul, , South Korea

Site Status

Samsung Medical Center, Division of Cardiology

Seoul, , South Korea

Site Status

"The Catholic University of Korea, Seoul St. Mary's Hospital Department of Cardiology"

Seoul, , South Korea

Site Status

Hosp Vall D'Hebron - Barcelona - Pneumology

Barcelona, , Spain

Site Status

Clinic-Barcelona

Barcelona, , Spain

Site Status

Hospital 12 Octubre

Madrid, , Spain

Site Status

Sahlgrenska Universitetssjukhuset, Kardiologi

Gothenburg, , Sweden

Site Status

Linköping University Hospital, Cardiology

Linköping, , Sweden

Site Status

Umeå University Hospital, Cardiology (Umeå)

Umeå, , Sweden

Site Status

Uppsala Akademiska Sjukhuset, Kardiologkliniken 50F

Uppsala, , Sweden

Site Status

University Hospital Basel Division of Pneumology

Basel, , Switzerland

Site Status

Universitätsspital Bern, Clinic for Pneumology (Inselspital)

Bern, , Switzerland

Site Status

HUG Hôpitaux Universitaires de Genève; Pneumology, PAH

Geneva, , Switzerland

Site Status

Kantonsspital St. Gallen Klinik für Pneumologie

Sankt Gallen, , Switzerland

Site Status

Kaohsiung Veterans General Hospital (KVGH)

Kaohsiung City, , Taiwan

Site Status

National Taiwan University Hospital / Department of Surgery

Taipei, , Taiwan

Site Status

Srinagarind Hospital, Khon Kaen University, Division of Allergy-Immunology and Rheumatology, Department of Medicine

Khon Kaen, , Thailand

Site Status

Çukurova Üniversitesi Tıp Fakültesi Kardiyoloji Anabilim Dalı

Adana, , Turkey (Türkiye)

Site Status

Istanbul Üniversitesi Kardiyoloji Enstitisü

Istanbul, , Turkey (Türkiye)

Site Status

Marmara Üniversitesi Tip Fakultesi Kardiyoloji Anabilim Dali

Istanbul, , Turkey (Türkiye)

Site Status

Dokuz Eylül Üniversitesi Tıp Fakültesi Kardiyoloji Anabilim Dalı

Izmir, , Turkey (Türkiye)

Site Status

"Dnipropetrovsk State Medical Academy, Municipal Institution ""Dnipropetrovsk Regional Clinic Diagnostic Center""

Dnipropetrovsk, , Ukraine

Site Status

Health Care Municipal Institution, City Clinical Hospital #13

Kharkiv, , Ukraine

Site Status

Public Institution "F.H. Yanovski Phthisiology and Pulmonology National Institute Under Ukrainian Academy of Medical Sciences"

Kyiv, , Ukraine

Site Status

Lviv Regional Clinical Hospital

Lviv, , Ukraine

Site Status

Golden Jubilee - Pulm Vascular Unit

Glasgow, , United Kingdom

Site Status

Royal Free & Ucms Rheumatology Unit

London, , United Kingdom

Site Status

Hammersmith

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belarus Belgium Canada Chile China Colombia Czechia Denmark France Germany Greece Hungary India Ireland Israel Italy Malaysia Mexico Netherlands Peru Poland Romania Russia Serbia Singapore Slovakia South Korea Spain Sweden Switzerland Taiwan Thailand Turkey (Türkiye) Ukraine United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.

Reference Type RESULT
PMID: 26699168 (View on PubMed)

Benza RL, Chin KM, Gaine S, Galie N, Hoeper MM, Lang IM, McLaughlin VV, Sitbon O, Doad G, Yen J, Tang X, Tapson V. Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: A post-hoc analysis of the GRIPHON study. J Heart Lung Transplant. 2024 Dec;43(12):1998-2007. doi: 10.1016/j.healun.2024.08.019. Epub 2024 Aug 31.

Reference Type DERIVED
PMID: 39222737 (View on PubMed)

Galie N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, McLaughlin VV, Lassen C, Rubin LJ, Hsu Schmitz SF, Sitbon O, Tapson VF, Chin KM. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Adv Ther. 2022 Jan;39(1):796-810. doi: 10.1007/s12325-021-01898-1. Epub 2021 Oct 30.

Reference Type DERIVED
PMID: 34727317 (View on PubMed)

Gaine S, Sitbon O, Channick RN, Chin KM, Sauter R, Galie N, Hoeper MM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson V, Ghofrani HA, Lang I. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. Chest. 2021 Jul;160(1):277-286. doi: 10.1016/j.chest.2021.01.066. Epub 2021 Feb 3.

Reference Type DERIVED
PMID: 33545163 (View on PubMed)

Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation. 2019 May 21;139(21):2440-2450. doi: 10.1161/CIRCULATIONAHA.118.039360.

Reference Type DERIVED
PMID: 30982349 (View on PubMed)

McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galie N. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. J Am Coll Cardiol. 2018 Feb 20;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010.

Reference Type DERIVED
PMID: 29447737 (View on PubMed)

Coghlan JG, Channick R, Chin K, Di Scala L, Galie N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47. doi: 10.1007/s40256-017-0262-z.

Reference Type DERIVED
PMID: 29307087 (View on PubMed)

Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galie N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Hoeper MM. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017 Aug 17;50(2):1602493. doi: 10.1183/13993003.02493-2016. Print 2017 Aug.

Reference Type DERIVED
PMID: 28818881 (View on PubMed)

Krause A, Machacek M, Lott D, Hurst N, Bruderer S, Dingemanse J. Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension. CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):477-485. doi: 10.1002/psp4.12202. Epub 2017 May 27.

Reference Type DERIVED
PMID: 28556581 (View on PubMed)

Skoro-Sajer N, Lang IM. Selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2014 Feb;15(3):429-36. doi: 10.1517/14656566.2014.876007. Epub 2014 Jan 7.

Reference Type DERIVED
PMID: 24392948 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AC-065A302

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

rhBNP in Type 3 Pulmonary Hypertension
NCT05716984 UNKNOWN PHASE4